Global IPO activity is accelerating across major markets, led by ambitious U.S. listings from Anthropic, Solidigm, Oura, EG Group and Blockchain.com. Europe sees Airtel Money moving ahead in London, while Asia-Pacific features large offerings from Firmus, Dongshan Precision, Asset World, Mynt, ESWIN Computing and Toggle. In MENA, MNT-Halan is preparing an Egyptian listing. Together, the deals highlight strong investor appetite, selective market conditions, shifting valuations and a growing pipeline of technology, fintech, infrastructure and consumer IPOs across global capital markets.

Reuters reports that Airtel Money is targeting a valuation of approximately $7 billion in its London IPO, which could become the city’s largest offering since September 2025. IPOX® Associate Lukas Muehlbauer said the deal demonstrates London’s ability to attract sizable international listings while also reflecting a buyer’s market. He noted that companies must remain realistic about valuation as Airtel Money prepares to raise about $703 million through the sale of 270 million shares ahead of its October debut.

Reuters reports that Oura postponed its planned U.S. IPO as market volatility and higher interest rates increased investor caution toward new listings. IPOX® Associate Lukas Muehlbauer commented that higher rates are making investors more selective, particularly on growth valuations, while noting that the IPO window remains open. He also highlighted reported demand for Oura’s offering, which was said to be around four times oversubscribed, and pointed to Anthropic’s planned IPO as an important upcoming market test.

Global IPO activity accelerated across major markets, led by large technology, infrastructure, fintech and healthcare offerings. Nscale, Oura, Accelevation, ADARx and Bamboo Insurance drove U.S. activity, while Anthropic continued IPO preparations. In Europe, Airtel Money advanced its London listing and Trafigura prepared Volare Shipping for Oslo. Asia-Pacific remained especially active, with Firmus, Mynt, EcoCeres, Kinwong Electronic, Direct Drive Tech and Camsense pursuing sizable listings across Australia, the Philippines and Hong Kong. Investor demand remains focused on AI-linked and growth companies.

Reuters reports that Accelevation is targeting a valuation of up to $5.37 billion in its U.S. IPO, seeking to raise up to $720 million. IPOX® Vice President Kat Liu said investors are becoming more selective as AI infrastructure offerings expand, focusing on companies’ value-chain positioning, backlog quality, and ability to convert demand into revenue, margins, and cash flow. Accelevation provides power distribution, cooling, and modular infrastructure for data centers supporting growing AI computing demand.

IPOX® CEO Josef Schuster commented in Barron's on how growing retail access to IPO allocations through platforms such as Robinhood, SoFi and Coinbase could influence short-term trading in newly listed companies. Discussing Oura’s upcoming IPO, Schuster noted that restrictions on future IPO access may discourage investors from quickly selling allocated shares, potentially affecting early trading dynamics. The article also highlighted IPOX®’s broader role in IPO market research and its index tracked by the First Trust US Equity Opportunities ETF.

IPOX® Associate Lukas Muehlbauer was interviewed by Kauppalehti, Finland’s leading business and financial newspaper, about Oura’s planned U.S. IPO and growth outlook. The article examines Oura’s strong revenue momentum, targeted $12.8–14.1 billion valuation and offering structure. Muehlbauer discussed how the valuation reflects significant future growth expectations and noted that much of the stock being offered comes from existing shareholders, meaning Oura itself is expected to receive only a portion of the proceeds raised through the transaction as part of the IPO.

Reuters reports that ADARx Pharmaceuticals raised $446.3 million in an upsized U.S. IPO, with shares opening 30% above the $17 offer price. IPOX® Associate Lukas Muehlbauer, who commented ahead of the offering on AbbVie’s backing and biotech investor selectivity, spoke with Reuters again after the company began trading. He highlighted AbbVie’s validation, ADARx’s Phase 3 lead drug and broader development platform, while noting that investors remain focused on mature clinical assets and key catalyst milestones across the biotech IPO market.

IPOX® VP Kat Liu comments on Oura’s planned U.S. IPO, which targets a fully diluted valuation of about $15.6 billion and could raise up to $2.2 billion. Liu highlighted Oura’s beginner-friendly, fashionable positioning in wearables, while noting that the valuation reflects expectations for continued strong growth and a greater shift toward higher-margin recurring revenue. Oura is expected to price next week and trade on Nasdaq under the ticker OURA, following its fall roadshow launch.

Global IPO activity this week featured several large planned offerings alongside notable delays. Firmus Technologies is seeking up to $5 billion in Australia, while Bamboo Insurance targets up to $700 million in New York. BASF advanced plans for a major Frankfurt listing, and Revolut and Vue explored future London-linked IPOs. Holtec, Dusk and Forms Syntron postponed or shelved offerings. Other deals included Linjemontage in Stockholm, Wiluna Mining in Australia and RoboTechnik’s $800 million Hong Kong secondary listing during the period.

IPOX® VP Kat Liu commented in Reuters on Orion180 Insurance’s Nasdaq debut and the excess and surplus insurance market. Liu explained that E&S carriers serve risks many traditional insurers cannot or do not want to write on standard terms, with greater flexibility in pricing, coverage limits and policy design. She added that Orion180’s opportunity has been accelerated by a cyclical dislocation as larger insurers pull back, rather than depending solely on those market conditions for its growth in the sector.

Reuters cited IPOX® Associate Lukas Muehlbauer on Holtec’s suspended U.S. IPO, linking the company’s investment case to expectations for higher electricity demand from data centres amid the AI boom. Muehlbauer said the broader IPO pipeline should remain active without widespread postponements, while noting investor concerns around AI development, interest rates, and weak nuclear-sector performance. “The underlying demand for energy has not disappeared, but investors are becoming more selective about how much they are willing to pay today for future growth.”

IPOX® Associate Lukas Muehlbauer commented on Altera’s planned U.S. IPO, highlighting investor focus on the chipmaker’s exposure to hyperscalers and AI infrastructure demand. Reuters reported that Altera, backed by Silver Lake and Intel, has confidentially filed to go public and could raise more than $2 billion. Muehlbauer noted that whether hyperscalers remain a material part of Altera’s customer base will be an important consideration for investors once the company’s public filing becomes available.

IPOX® VP Kat Liu said in Reuters coverage that SPAC mergers can provide a more flexible route for defense and space companies with government contracts, strategic backing or clear growth pipelines that lack the revenue scale or predictability required for traditional IPOs. Reuters reports six defense and space-related companies have announced SPAC mergers in 2026, double the total in 2025, as investor appetite surges. The sector is also benefiting from rising government spending and strong demand for satellite, defense and aerospace technologies this year.

IPOX® VP Kat Liu said insurance companies’ recurring revenue and resilient demand are attractive in volatile markets as Reuters covered CVC-backed Bamboo Insurance’s planned U.S. IPO. Bamboo is targeting a valuation of up to $3.24 billion, with selling shareholders seeking as much as $700 million. Liu also noted that Bamboo’s managing general underwriter model creates dependence on insurance carriers and capacity providers. The company plans to list on the NYSE under the ticker “BMB” amid relatively strong insurance IPO performance.